Silo Pharma (SILO) Total Non-Current Liabilities (2012 - 2026)
Silo Pharma (SILO) posted Total Non-Current Liabilities of $631451.0 for Q1 2026, down 2.78% sequentially from $649476.0 in Q4 2025, and down 10.25% YoY from $703553.0 in Q1 2025.
Silo Pharma (SILO) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Silo Pharma has reported Total Non-Current Liabilities for 8 years, with the latest figure at $631451.0 in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 10.25% year-over-year to $631451.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $631451.0 (down 10.25% YoY) and the FY2025 annual result came in at $649476.0, down 9.99% from the prior year.
- Total Non-Current Liabilities slipped to $631451.0 in Q1 2026 per SILO's latest filing, from $649476.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $919859.0 in Q1 2022 and troughed at $631451.0 in Q1 2026.
- A 5-year average of $775654.6 and a median of $775654.0 in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2026: Total Non-Current Liabilities slipped 2.8% in 2022, then retreated 10.25% in 2026.
- Over 5 years, Total Non-Current Liabilities stood at $865782.0 in 2022, then retreated by 8.33% to $793680.0 in 2023, then declined by 9.08% to $721578.0 in 2024, then dropped by 9.99% to $649476.0 in 2025, then slipped by 2.78% to $631451.0 in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $631451.0, $649476.0, and $667502.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Silo Pharma | 2.92 Mn | 2.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 631,451.00 |
| Dec 31, 2025 | 649,476.00 |
| Sep 30, 2025 | 667,502.00 |
| Jun 30, 2025 | 685,527.00 |
| Mar 31, 2025 | 703,553.00 |
| Dec 31, 2024 | 721,578.00 |
| Sep 30, 2024 | 739,604.00 |
| Jun 30, 2024 | 757,629.00 |
| Mar 31, 2024 | 775,654.00 |
| Dec 31, 2023 | 793,680.00 |
| Sep 30, 2023 | 811,706.00 |
| Jun 30, 2023 | 829,731.00 |
| Mar 31, 2023 | 847,757.00 |
| Dec 31, 2022 | 865,782.00 |
| Sep 30, 2022 | 883,807.00 |
| Jun 30, 2022 | 901,833.00 |
| Mar 31, 2022 | 919,859.00 |
| Dec 31, 2021 | 937,884.00 |
| Sep 30, 2021 | 955,909.00 |
| Jun 30, 2021 | 973,935.00 |